HSBC Holdings’s Revance Therapeutics, Inc. RVNC Stock Holding History

HSBC Holdings’s Portfolio RVNC Stock Details RVNC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-12,111	Closed	-$36.8K	–	3339
2024 Q4	$36.8K	Sell	12,111 -1,158,327	-99%	-$5.05M	﹤0.01%	3017
2024 Q3	$6.21M	Buy	1,170,438 +1,155,481	+7,725%	+$5.74M	﹤0.01%	1057
2024 Q2	$38.5K	Buy	+14,957	New	+$51.1K	﹤0.01%	2840
2023 Q1	–	Sell	-19,000	Closed	-$350K	–	3122
2022 Q4	$350K	Buy	+19,000	New	+$435K	﹤0.01%	2455
2022 Q3	–	Sell	-88,773	Closed	-$1.23M	–	3328
2022 Q2	$1.23M	Buy	88,773 +28,665	+48%	+$441K	﹤0.01%	1812
2022 Q1	$1.17M	Buy	60,108 +2,078	+4%	+$31.5K	﹤0.01%	1850
2021 Q4	$947K	Sell	58,030 -7,751	-12%	-$129K	﹤0.01%	2087
2021 Q3	$1.83M	Buy	65,781 +55,603	+546%	+$1.59M	﹤0.01%	1572
2021 Q2	$301K	Buy	+10,178	New	+$294K	﹤0.01%	2515

Other funds holding RVNC

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return

HSBC Holdings's RVNC Position: Q1 2025 in Review

HSBC Holdings sold out of Revance Therapeutics, Inc. (RVNC) in Q1 2025, closing a stake of 12,111 shares — an estimated $36.8K sold.

HSBC Holdings first reported a position in RVNC in Q2 2021 and held it in 9 quarters. The position peaked at $6.21M in Q3 2024. 1 fund tracked by Wall St. Rank holds RVNC as of Q1 2025.

HSBC Holdings reported no remaining Revance Therapeutics, Inc. position as of Q1 2025 after selling out during the quarter.
HSBC Holdings sold 12,111 Revance Therapeutics, Inc. shares in Q1 2025, an estimated $36.8K.
HSBC Holdings first reported a position in Revance Therapeutics, Inc. in Q2 2021 and held it in 9 quarters.
HSBC Holdings's Revance Therapeutics, Inc. position peaked at $6.21M in Q3 2024.
1 fund tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2025.

Based on HSBC Holdings's 13F filing for Q1 2025, filed 14 May 2025.